Methodological considerations in clinical trials for new MDR-TB treatment regimens

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 12, 2016, Pages S4-S7

  Phillips, P P J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical trials; Evidence based medicine; MDR TB; Methodology

Indexed keywords

BEDAQUILINE; DELAMANID; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE POLICY; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT DURATION; METHODOLOGY; PATIENT SELECTION; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; FOLLOW-UP STUDIES; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 85016126101     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.16.0061     Document Type: Article

References (23)

1. th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2010.
2. Diacon A H, Pym A, Grobusch M P, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
3. Gler M T, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
4. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
5. Ahuja S D, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLOS MED 2012; 9: e1001300.
6. World Health Organization. Global tuberculosis report, 2015. WHO/HTM/TB/2015.22. Geneva, Switzerland: WHO, 2015.
7. Piubello A, Harouna S H, Souleymane M B, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188-1194.
8. Van Deun A, Maug A K J Salim M A H, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
9. Wason J M, Stecher L, Mander A P. Correcting for multiple-testing in multi-arm trials: is it necessary and is it done? Trials 2014; 15: 364.
10. Parmar M K, Carpenter J, Sydes M R. More multiarm randomised trials of superiority are needed. Lancet 2014; 384: 283-284.
11. Davies G R, Phillips P P, Jaki T. Adaptive clinical trials in tuberculosis: applications, challenges and solutions. Int J Tuberc Lung Dis 2015; 19: 626-634.
12. Nachman S, Ahmed A, Amanullah F, et al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis 2015; 15: 711-720.
13. Gupta A, Mathad J S, Abdel-Rahman S M, et al. Toward earlier inclusion of pregnant and postpartum women in tuberculosis drug trials: consensus statements from an international expert panel. Clin Infect Dis 2016; 62: 761-769.
14. International Council on Harmonisation Expert Working Group. Choice of control group and related issues in clinical trials. Geneva, Switzerland: ICH Harmonised Tripartite Guideline Current Step 2000; 4: E10.
15. Adebamowo C, Bah-Sow O, Binka F, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet 2014; 384: 1423-1424.
16. Nelson R M, Roth-Cline M, Prohaska K, Cox E, Borio L, Temple R. Right job, wrong tool: a commentary on designing clinical trials for Ebola virus disease. Am J Bioeth 2015; 15: 33-36.
17. Aung K J, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-1187.
18. Nunn A J, Phillips P P J Mitchison D A. Timing of relapse in short-course chemotherapy trials for tuberculosis [Short communication]. Int J Tuberc Lung Dis 2010; 14: 241-242.
19. Johnson J L, Thiel B A. Time until relapse in tuberculosis treatment trials: implication for Phase 3 trial design. Am J Respir Crit Care Med 2012; 186: 464.
20. Gillespie S H, Crook A M, McHugh T D, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371: 1577-1587.
21. Jindani A, Harrison T S, Nunn A J, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371: 1599-1608.
22. Merle C S, Fielding K, Sow O B, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014; 371: 1588-1598.
23. Furin J, Alirol E, Allen E, et al. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis 2016; 20: 290-294.